(Corrected)

Session of 2017

House Substitute for SENATE BILL No. 51

By Committee on Health and Human Services

3-14

AN ACT concerning controlled substances; the state board of pharmacy; relating to scheduling of controlled substance analogs, controlled substances and new drugs; emergency scheduling; amending K.S.A. 2016 Supp. 21-5701, 65-4101, 65-4102, 65-4105, 65-4107, 65-4111 and 65-4113 and repealing the existing sections.

Be it enacted by the Legislature of the State of Kansas:

Section 1. K.S.A. 2016 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2016 Supp. 21-5701 through 21-5717, and amendments thereto: (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

- (b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and *at least one of the following*:
- (A) The chemical structure of which the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto:
- (B) which the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, which the such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
 - (2) "Controlled substance analog" does not include:
 - (A) A controlled substance;
- (B) a substance for which there is an approved new drug application; or

- (c) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.
- (d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.
 - "Drug" means: (e)

7

8

9

10

11 12

13 14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

- (1) Substances recognized as drugs in the official United States pharmacopoeia pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them:
- (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or animals;
- (3) substances, other than food, intended to affect the structure or any function of the body of man or animals: and
- (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.
- (f) "Drug paraphernalia" means all equipment and materials of any kind which are used, or primarily intended or designed for use in planting. propagating, cultivating. growing. harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act. "Drug paraphernalia" shall include, but is not limited to:
- (1) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant which is a controlled substance or from which a controlled substance can be derived;
- (2) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;
- (3) isomerization devices used or intended for use in increasing the potency of any species of plant which is a controlled substance;
- (4) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;

5

6

7

8

9

10

11 12

13 14

15 16

17

18 19

20

21

22

23

24

25

26

27 28

29

34

36

- 1 (5) scales and balances used or intended for use in weighing or 2 measuring controlled substances;
 - (6) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose, which are used or intended for use in cutting controlled substances;
 - (7) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
 - (8) blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
 - (9) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
 - (10) containers and other objects used or intended for use in storing or concealing controlled substances;
 - (11) hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body;
 - (12) objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:
 - (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls;
 - (B) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
 - (C) carburetion pipes, glass or other heat resistant tubes or any other device used—or, intended to be used; or designed to be used to cause vaporization of a controlled substance for inhalation;
 - (D) smoking and carburetion masks;
- 30 (E) roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand;
- 33 (F) miniature cocaine spoons and cocaine vials;
 - (G) chamber smoking pipes;
- 35 (H) carburetor smoking pipes;
 - (I) electric smoking pipes;
- 37 (J) air-driven smoking pipes;
 - (K) chillums;
- 39 (L) bongs;
- 40 (M) ice pipes or chillers;
- 41 (N) any smoking pipe manufactured to disguise its intended purpose;
- 42 (O) wired cigarette papers; or
- 43 (P) cocaine freebase kits.

"Drug paraphernalia" shall not include any products, chemicals or materials described in subsection (a) of K.S.A. 2016 Supp. 21-5709(a), and amendments thereto.

- (g) "Immediate precursor" means a substance which the *state* board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
 - (h) "Isomer" means all enantiomers and diastereomers.
- (i) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:
- (1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
- (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or
- (2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose, which are intended for use in cutting a controlled substance.
- (j) "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. "Marijuana" does not include{: (1)} The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant which is incapable of germination{; or (2) any substance listed in schedules II through V of the uniform controlled substances act}.
 - (k) "Minor" means a person under 18 years of age.
- (l) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or

3 4

5

6

7

8

9

10

11

12 13

14

15

16

17

18 19

20 21

22

23

24 25

26

27 28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:

- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
 - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.
- (m) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.
- "Opium poppy" means the plant of the species Papaver somniferum 1. except its seeds.
- (o) "Person" means individual, corporation, government governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.
- (p) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (q) "Possession" means having joint or exclusive control over an item with knowledge of and intent to have such control or knowingly keeping some item in a place where the person has some measure of access and right of control.
- (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence

2 (s) "Simulated controlled substance" means any product which 3 identifies itself by a common name or slang term associated with a 4 controlled substance and which indicates on its label or accompanying 5 promotional material that the product simulates the effect of a controlled

substance.

- Sec. 2. K.S.A. 2016 Supp. 65-4101 is hereby amended to read as follows: 65-4101. As used in this act: (a) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:
- (1) A practitioner or pursuant to the lawful direction of a practitioner; or
 - (2) the patient or research subject at the direction and in the presence of the practitioner.
 - (b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor or dispenser. It does not include a common carrier, public warehouseman or employee of the carrier or warehouseman.
 - (c) "Application service provider" means an entity that sells electronic prescription or pharmacy prescription applications as a hosted service where the entity controls access to the application and maintains the software and records on its server.
 - (d) "Board" means the state board of pharmacy.
 - (e) "Bureau" means the bureau of narcotics and dangerous drugs, United States department of justice, or its successor agency.
 - (f) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
 - (g) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
 - (A) The chemical structure of which the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
 - (B) which the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
 - (C) with respect to a particular individual,—which such individual represents or intends *the substance* to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to

2

3

4

5

6

7

8

9

10

11 12

13

14

15 16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 35

36

37

38

39

40

41

42

43

the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.

- (2) "Controlled substance analog" does not include:
- (A) A controlled substance;
- a substance for which there is an approved new drug application; (B) or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
- (h) "Counterfeit substance" means a controlled substance which, or the container or labeling of which, without authorization bears the trademark, trade name or other identifying mark, imprint, number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance
- (i) "Cultivate" means the planting or promotion of growth of five or more plants which contain or can produce controlled substances.
- (j) "DEA" means the U.S. department of justice, drug enforcement administration.
- (k) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.
- "Dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the packaging, labeling or compounding necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level practitioner.
- (m) "Dispenser" means a practitioner or pharmacist who dispenses, or a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto.
- (n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.
 - (o) "Distributor" means a person who distributes.
- (p) "Drug" means: (1) Substances recognized as drugs in the official United States—pharmacopoeia pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them; (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human or animals; (3) substances (other than food) intended to affect the structure or any function of the body of human or animals; and (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3).

- (q) "Immediate precursor" means a substance which the board has found to be and by rule and regulation designates as being the principal compound commonly used or produced primarily for use and which is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
- (r) "Electronic prescription" means an electronically prepared prescription that is authorized and transmitted from the prescriber to the pharmacy by means of electronic transmission.
- (s) "Electronic prescription application" means software that is used to create electronic prescriptions and that is intended to be installed on the prescriber's computers and servers where access and records are controlled by the prescriber.
- (t) "Electronic signature" means a confidential personalized digital key, code, number or other method for secure electronic data transmissions which identifies a particular person as the source of the message, authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission.
- (u) "Electronic transmission" means the transmission of an electronic prescription, formatted as an electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer, where the data file is imported into the pharmacy prescription application.
- (v) "Electronically prepared prescription" means a prescription that is generated using an electronic prescription application.
- (w) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but is not limited to, transmission of a written prescription between the prescriber's fax machine and the pharmacy's fax machine; transmission of an electronically prepared prescription from the prescriber's electronic prescription application to the pharmacy's fax machine, computer or printer; or transmission of an electronically prepared prescription from the prescriber's fax machine to the pharmacy's fax machine, computer or printer.
- (x) "Intermediary" means any technology system that receives and transmits an electronic prescription between the prescriber and the pharmacy.
 - (y) "Isomer" means all enantiomers and diastereomers.
- (z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of

3

4

5

6

7

8

9

10

11 12

13

14

15 16

17

18 19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

extraction and chemical synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:

- (1) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance.
- "Marijuana" means all parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its seeds or resin. It does not include {: (1)} The mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil; or cake or the sterilized seed of the plant which is incapable of germination {; or (2) any substance listed in schedules II through V of the uniform controlled substances act.
- (bb) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425, and amendments thereto.
- (cc) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice of midwifery under the independent practice of midwifery act, an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs pursuant to a written protocol with a responsible physician under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto.
- (dd) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances

2

3

4

5

6 7

8

9

10

11 12

13 14

15

16

17

18

19

20

21

22

23

24

25

26 27

28

29

30

31

32 33

34 35

36

37

38

39

40 41

42 43 referred to in paragraph (1) but not including the isoguinoline alkaloids of opium;

- (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves which do not contain cocaine or ecgonine.
- (ee) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.
- (ff) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (gg) "Person" means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership or association or any other legal entity.
- "Pharmacist" means any natural person licensed under K.S.A. 65-1625 et seg., and amendments thereto, to practice pharmacy.
- (ii) "Pharmacist intern" means: (1) A student currently enrolled in an accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving such person's internship; or (3) a graduate of a pharmacy program located outside of the United States which is not accredited and who had successfully passed equivalency examinations approved by the board.
- "Pharmacy prescription application" means software that is used to process prescription information, is installed on a pharmacy's computers and servers, and is controlled by the pharmacy.
- (kk) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (II) "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance.
 - "Prescriber" means a practitioner or a mid-level practitioner.
- "Production" includes the manufacture, planting, cultivation, growing or harvesting of a controlled substance.
- (oo) "Readily retrievable" means that records kept by automatic data processing applications or other electronic or mechanized recordkeeping

systems can be separated out from all other records within a reasonable time not to exceed 48 hours of a request from the board or other authorized agent or that hard-copy records are kept on which certain items are asterisked, redlined or in some other manner visually identifiable apart from other items appearing on the records.

- (pp) "Ultimate user" means a person who lawfully possesses a controlled substance for such person's own use or for the use of a member of such person's household or for administering to an animal owned by such person or by a member of such person's household.
- Sec. 3. K.S.A. 2016 Supp. 65-4102 is hereby amended to read as follows: 65-4102. (a) The board shall administer this act and may adopt rules and regulations relating to the registration and control of the manufacture, distribution and dispensing of controlled substances within this state. All rules and regulations of the board shall be adopted in conformance with article 4 of chapter 77 of the Kansas Statutes Annotated, and amendments thereto, and the procedures prescribed by this act.
- (b) Annually, the board shall submit to the speaker of the house of representatives and the president of the senate a report on substances proposed by the board for scheduling, rescheduling or deletion by the legislature with respect to any one of the schedules as set forth in this act, and reasons for the proposal shall be submitted by the board therewith and a report of the substances scheduled during the preceding calendar year under subsection (e), if any, along with the reasons for the proposal and the scheduling. In making a determination regarding the proposal to schedule, reschedule or delete a substance, the board shall consider the following:
 - (1) The actual or relative potential for abuse;
 - (2) the scientific evidence of its pharmacological effect, if known;
 - (3) the state of current scientific knowledge regarding the substance;
 - (4) the history and current pattern of abuse;
 - (5) the scope, duration and significance of abuse;
 - (6) the risk to the public health;
- (7) the potential of the substance to produce psychological or physiological dependence liability; and
- (8) whether the substance is an immediate precursor of a substance already controlled under this article.
- (c) The board shall not include any nonnarcotic substance within a schedule if such substance may be lawfully sold over the counter without a prescription under the federal food, drug and cosmetic act.
- (d) Authority to control under this section does not extend to distilled spirits, wine, malt beverages or tobacco.
- (e) (1) Upon receipt of notice under K.S.A. 2016 Supp. 21-5715, and amendments thereto, or upon the board's finding of an imminent hazard to

3

4

5

6

7

8

9

10

11 12

13

14

15

16 17

18

19

20

21

22

23

24

25

26 27

28

29

30

31

32

33

34

35

36

37

38

the public safety, the board shall initiate scheduling of the controlled substance analog or a new drug, as defined in this subsection, on an emergency basis pursuant to this subsection. The scheduling of a substance under this subsection expires one year on July 1 of the following calendar year after the adoption of the scheduling rule and regulation.

- (2) With respect to the finding of an imminent hazard to the public safety, the board shall consider whether the substance has been scheduled on a temporary basis under federal law or factors set forth in subsections (b)(4), (5) and (6), and may also consider clandestine importation, manufacture or distribution, and if available, information concerning the other factors set forth in subsection (b).
- (3) A rule and regulation may not be adopted under this subsection until the board initiates a rulemaking proceeding under subsection (a) with respect to the substance. A rule adopted under this subsection lapses upon the conclusion of the rulemaking proceeding initiated under subsection (a) with respect to the substance. A rule and regulation adopted under this subsection shall expire on July 1 of the calendar year following the year of its adoption.
- (4) As used in this subsection, "new drug" means: (A) Any drug the composition of which is such that such drug is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs, as safe and effective for use under the conditions prescribed, recommended or suggested in the labeling thereof; or (B) any drug the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but that has not, other than in such investigations, been used to a material extent or for a material time under such conditions. The term "new drug" shall not include amygdalin (laetrile).
- Sec. 4. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as follows: 65-4105. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.
- (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
- Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-39 (1) 40 phenylacetamide)......9821
- Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-41 (2) piperidinyl]-N-phenylacetamide)......9815 42 43
 - Acetylmethadol......9601 (3)

(30)(34)

Furethidine 9626

1	(5)	Codeine-N-Oxide	9053
2	(6)	Cyprenorphine	9054
3	(7)	Desomorphine	9055
4	(8)	Dihydromorphine	9145
5	(9)	Drotebanol	9335
6	(10)	Etorphine (except hydrochloride salt)	9056
7	(11)	Heroin 9200	
8	(12)	Hydromorphinol	9301
9	(13)	Methyldesorphine	
10	(14)	Methyldihydromorphine	9304
11	(15)	Morphine methylbromide	9305
12	(16)	Morphine methylsulfonate	9306
13	(17)	Morphine-N-Oxide	
14	(18)	Myrophine	
15	(19)	Nicocodeine	9309
16	(20)	Nicomorphine	
17	(21)	Normorphine	9313
18	(22)	Pholcodine	9314
19	(23)	Thebacon	9315
20	(d)	Any material, compound, mixture or preparation which co	ontains
21	any qu	nantity of the following hallucinogenic substances, their	salts,
22		s and salts of isomers, unless specifically excepted, whenever	
23		ce of these salts, isomers and salts of isomers is possible wit	hin the
24	specific	chemical designation:	
25	(1)	Alpha-ethyltryptamine 7249 Some trade or other names:	
26		etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3	3-
27		(2-aminobutyl) indole; α -ET; and AET.	
28	(2)	4-bromo-2,5-dimethoxy-amphetamine	7391
29		Some trade or other names: 4-bromo-2,5-dimethoxy-alph	a-
30		methylphenethylamine; 4-bromo-2,5-DMA.	
31	(2) (3)	2,5-dimethoxyamphetamine	
32		Some trade or other names: 2,5-dimethoxy-alpha-methyl-	
33		phenethylamine; 2,5-DMA.	
34	(3)(4)	4-methoxyamphetamine	7411
35		Some trade or other names: 4-methoxy-alpha-methylphen	ie-
36		thylamine; paramethoxyamphetamine; PMA.	
37	(4)(5)	5-methoxy-3,4-methylenedioxy-amphetamine	
38	(5) (6)	4-methyl-2,5-dimethoxy-amphetamine	
39		Some trade or other names: 4-methyl-2,5-dimethoxy-alph	ıa-
40		methylphenethylamine; "DOM"; and "STP".	
41	(6) (7)	3,4-methylenedioxy amphetamine	
42	(7) (8)	3,4-methylenedioxymethamphetamine (MDMA)	
43	$\frac{(8)}{(9)}$	3.4-methylenedioxy-N-ethylamphetamine (also known as	

1		N-ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamin	ne,
2		N-ethyl MDA, MDE, and MDEA)	.7404
3	$\frac{(9)}{(10)}$	N-hydroxy-3,4-methylenedioxyamphetamine (also known	
4	` / (/	as N-hydroxy-alpha-methyl-3,4-(methylenedioxy)	
5		phenethylamine, and N-hydroxy MDA)	.7402
6	(10)(11)	3,4,5-trimethoxy amphetamine	
7	(11) (12)	Bufotenine	
8	()()	Some trade or other names: 3-(Beta-Dimethylaminoethyl)-	
9		5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,	
10		N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine:	
11		mappine.	
12	(12)(13)	Diethyltryptamine	.7434
13	()()	Some trade or other names: N,N-Diethyltryptamine; DET.	
14	(13)(14)	Dimethyltryptamine	7435
15	(15)(11)	Some trade or other names: DMT.	., 155
16	(14)(15)	Ibogaine	7260
17	(11)(10)	Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,1	
18		octahydro-2-methoxy-6,9-methano -5H-pyrido[1',2':1,2]	<i>J</i>
19		azepino [5,4-b]indole; Tabernanthe iboga	
20	(15) (16)	Lysergic acid diethylamide	7315
21	(16) (17)	Marijuana	
22	(17) (18)	Mescaline	
23	(18) (19)	Parahexyl	
24	(10)(17)	Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-	./3/7
25		tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhex	<i>i</i> 1
26	(19) (20)	Peyote	
27 27	(17)(20)	Meaning all parts of the plant presently classified botanica	
28		as Lophophora williamsii Lemaire, whether growing or	11 y
29		not, the seeds thereof, any extract from any part of such pla	ant
30		and every compound, manufacture, salts, derivative, mixtu	
31		or preparation of such plant, its seeds or extracts.	10
32	(20) (21)	N-ethyl-3-piperidyl benzilate	7482
33	$\frac{(20)(21)}{(21)}(22)$	N-methyl-3-piperidyl benzilate	
34	$\frac{(21)(22)}{(23)}$	Psilocybin	
35	$\frac{(22)(23)}{(23)}$	Psilocyn	
36	(23)(24)	Some trade or other names: Psilocin.	.7430
37	(24)(25)	Ethylamine analog of phencyclidine	7/155
38	(27)(23)	Some trade or other names: N-ethyl-1-phenyl-cyclo-	.7433
39		hexylamine; (1-phenylcyclohexyl)ethylamine; N-(1-	
39 40		phenylcyclohexyl)ethylamine; cyclohexamine; PCE.	
40 41	(25) (26)	Pyrrolidine analog of phencyclidine	7/150
41 42	(23) (20)	Some trade or other names: 1-(1-phenylcyclohexyl)-	./438
42 43			
+3		pyrrolidine; PCPy; PHP.	

1		ethanamine
2		Some trade or other names: 25I–NBOMe; 2C–I–NBOMe; 25I;
3		Cimbi–5.
4	(48) (49)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)
5		ethanamine
6		Some trade or other names: 25C–NBOMe; 2C–C–NBOMe;
7		25C; Cimbi–82.
8	(49) (50)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
9		methoxybenzyl)ethanamine
10		
11		25B; Cimbi–36.
12	(50) (51)	2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
13		Some trade or other names: 25H-NBOMe.
14	(51) (52)	2-(2,5-dimethoxy-4-methylphenyl)-N-(2-
15		methoxybenzyl)ethanamine
16		Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.
17	(52) (53)	2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)
18		ethanamine
19		Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.
20	(e) A	ny material, compound, mixture or preparation which contains
21	any quant	ity of the following substances having a depressant effect on the
22	central ne	ervous system, including its salts, isomers, and salts of isomers
23	whenever	the existence of such salts, isomers, and salts of isomers is
24	possible v	vithin the specific chemical designation:
25	(1)	Etizolam Some trade or other names: (4-(2-chlorophenyl)-2-
26		ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a]
27		[1,4]diazepine)
28	(2)	Mecloqualone2572
29	(2) (3)	Methaqualone
30	(3) (4)	Gamma hydroxybutyric acid
31		nless specifically excepted or unless listed in another schedule,
32	any mate	rial, compound, mixture or preparation which contains any
33	quantity (of the following substances having a stimulant effect on the
34	central ne	rvous system, including its salts, isomers and salts of isomers:
35	(1)	Aminorex 1585 some other names: Aminoxaphen 2-amino-5-
36		phenyl-2-oxazoline or 4,5-dihydro-5-phenyl-2-oxazolamine
37	(2)	Fenethylline
38	(2) (3)	N-ethylamphetamine
39	(3) (4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-
40	. / . /	phenyl-2-oxazolamine)
41	(4)(5)	N,N-dimethylamphetamine (also known as N,N-alpha-
42		trimethyl-benzeneethanamine; N,N-alpha-
43		trimethylphenethylamine)

1		resinous extractives of Cannabis, sp. and/or synthetic
2		substances, derivatives, and their isomers with similar chemical
3		structure and pharmacological activity such as the following:
4		Delta 1 cis or trans tetrahydrocannabinol, and their optical
5		isomers Delta 6 cis or trans tetrahydrocannabinol, and their
6		optical isomers Delta 3,4 cis or trans tetrahydrocannabinol, and
7		its optical isomers (Since nomenclature of these substances is
8		not internationally standardized, compounds of these structures
9		regardless of numerical designation of atomic positions
10		covered.)
11	(2)	Naphthoylindoles
12		Any compound containing a 3-(1-naphthoyl)indole structure
13		with substitution at the nitrogen atom of the indole ring by an
14		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
16		ethyl group, whether or not further substituted in the indole ring
17		to any extent and whether or not substituted in the benzyl or
18		naphthyl ring to any extent.
19	(3)	Naphthylmethylindoles
20		Any compound containing a 1H-indol-3-yl-(1-
21		naphthyl)methane structure with substitution at the nitrogen
22		atom of the indole ring by an alkyl, haloalkyl, alkenyl,
23		cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-
24		piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or
25		not further substituted in the indole ring to any extent and
26		whether or not substituted in the benzyl or naphthyl ring to any
27		extent.
28	(4)	Naphthoylpyrroles
29	()	Any compound containing a 3-(1-naphthoyl)pyrrole structure
30		with substitution at the nitrogen atom of the pyrrole ring by an
31		alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
32		benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
33		morpholinyl)ethyl group whether or not further substituted in
34		the pyrrole ring to any extent, whether or not substituted in the
35		benzyl or naphthyl ring to any extent.
36	(5)	Naphthylmethylindenes
37	(0)	Any compound containing a naphthylideneindene structure with
38		substitution at the 3-position of the indene ring by an alkyl,
39		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, <i>benzyl</i> , 1-
10		(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
41		group whether or not further substituted in the indene ring to
12		any extent, whether or not substituted in the benzyl or naphthyl
13		ring to any extent.
		vo wiij viitoiit.

1 2 3 4 5 6 7 8	(6)	Phenylacetylindoles Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the benzyl or phenyl ring to any extent.
9 10 11 12 13 14 15	(7)	Cyclohexylphenols Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent.
16 17 18 19 20 21 22 23	(8)	Benzoylindoles Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, <i>benzyl</i> , 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the <i>benzyl</i> or phenyl ring to any extent.
24 25 26	(9)	2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone. Some trade or other names: WIN 55,212-2.
27 28 29	(10)	9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol Some trade or other names: HU-210, HU-211.
30 31 32 33 34 35 36 37 38 39	(11)	Tetramethylcyclopropanoylindoles Any compound containing a 3-tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the benzyl or tetramethylcyclopropyl rings to any
40 41 42 43	(12)	extent. Indole-3-carboxylate esters Any compound containing a 1H-indole-3-carboxylate ester structure with the ester oxygen bearing a naphthyl, quinolinyl,

Sec. 5. K.S.A. 2016 Supp. 65-4107 is hereby amended to read as follows: 65-4107. (a) The controlled substances listed in this section are included in schedule II and the number set forth opposite each drug or substance is the DEA controlled substances code which has been assigned to it.

31

32

33

34

35

36

37

38

39

40

41 42

- (b) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone and their respective salts, but including the following:
- (A) Raw opium......9600

1	(10)	Isomethadone	9226
2	(11)	Levomethorphan	
3	(12)	Levorphanol	9220
4	(13)	Metazocine	9240
5	(14)	Methadone	9250
6	(15)	Methadone-intermediate,4-cyano-2-dimethyl amino-4,4-	
7		diphenyl butane	9254
8	(16)	Moramide-intermediate, 2-methyl-3-morpholino-1, 1-	
9		diphenylpropane-carboxylic acid	9802
10	(17)	Pethidine (meperidine)	9230
11	(18)	Pethidine-intermediate-A, 4-cyano-1-methyl-4-	
12		phenylpiperidine	9232
13	(19)	Pethidine-intermediate-B, ethyl-4-phenyl-piperidine-4-	
14		carboxylate	9233
15	(20)	Pethidine-intermediate-C, 1-methyl-4-phenyl-piperidine-4-	
16		carboxylic acid	9234
17	(21)	Phenazocine	9715
18	(22)	Piminodine	9730
19	(23)	Racemethorphan	9732
20	(24)	Racemorphan	
21	(25)	Sufentanil	
22	(26)	Levo-alphacetyl methadol	
23		Some other names: levo-alpha-acetyl methadol, levomethad	.yl
24		acetate or LAAM.	
25	(27)	Remifentanil	
26	(28)	Tapentadol	
27	(29)	Thiafentanil	
28	(d)	Any material, compound, mixture, or preparation which co	
29		uantity of the following substances having a potential for	abuse
30		ated with a stimulant effect on the central nervous system:	
31	(1)	Amphetamine, its salts, optical isomers and salts of its optic	
32		isomers	
33	(2)	Phenmetrazine and its salts	1631
34	(3)	Methamphetamine, including its salts, isomers and salts of	
35		isomers	
36	(4)	Methylphenidate	1724
37	(5)	Lisdexamfetamine, its salts, isomers, and salts of its	
38		isomers	
39	(e)		
10		naterial, compound, mixture or preparation which contain	
11		ty of the following substances having a depressant effect of	
12		nervous system, including its salts, isomers and salts of is	
13	whenev	ver the existence of such salts, isomers and salts of isom	ners is

43

contains any quantity of the following substances including its salts, isomers and salts of isomers whenever the existence of such salts.

1	isomers and salts of isomers is possible within the specific c	hemical
2	designation and having a potential for abuse associated	with a
3	depressant effect on the central nervous system:	
4	(1) Alprazolam	
5	(2) Barbital	2145
6	(3) Bromazepam	2748
7	(4) Camazepam	
8	(5) Carisoprodol	
9	(6) Chloral betaine	2460
10	(7) Chloral hydrate	
11	(8) Chlordiazepoxide	2744
12	(9) Clobazam	2751
13	(10) Clonazepam	2737
14	(11) Clorazepate	2768
15	(12) Clotiazepam	2752
16	(13) Cloxazolam	2753
17	(14) Delorazepam	2754
18	(15) Diazepam	
19	(16) Dichloralphenazone	2467
20	(17) Estazolam	2756
21	(18) Ethchlorvynol	2540
22	(19) Ethinamate	2545
23	(20) Ethyl loflazepate	2758
24	(21) Fludiazepam	2759
25	(22) Flunitrazepam	2763
26	(23) Flurazepam	2767
27	(24) Fospropofol	2138
28	(25) Halazepam	2762
29	(26) Haloxazolam	2771
30	(27) Ketazolam	2772
31	(28) Loprazolam	2773
32	(29) Lorazepam	2885
33	(30) Lormetazepam	2774
34	(31) Mebutamate	2800
35	(32) Medazepam	2836
36	(33) Meprobamate	2820
37	(34) Methohexital	2264
38	(35) Methylphenobarbital (mephobarbital)	2250
39	(36) Midazolam	
10	(37) Nimetazepam	
11	(38) Nitrazepam	
12	(39) Nordiazepam	
13	(40) Oxazepam	

1	(6) Mefenorex1580
2	(7) Pemoline (including organometallic complexes and chelates
3	thereof)1530
4	(8) Phentermine1640
5	The provisions of this subsection (e)(8) shall expire on the date
6	phentermine and its salts and isomers are removed from schedule IV
7	of the federal controlled substances act (21 U.S.C. § 812; 21 code of
8	federal regulations 1308.14).
9	(9) Pipradrol1750
10	(10) SPA((-)-1-dimethylamino-1, 2-diphenylethane)1635
11	(11) Sibutramine1675
12	(12) Mondafinil1680
13	(f) Unless specifically excepted or unless listed in another
14	schedule, any material, compound, mixture or preparation-which that
15	contains any quantity of the following, including salts thereof:
16	(1) Pentazocine9709
17	(2) Butorphanol (including its optical isomers)9720
18	(3) Cannabidiol, when comprising the sole active ingredient of a drug
19	product approved by the United States food and drug administration:
20	Some other names for cannabidiol: $2-[(1R,6R)-3-Methyl-6-(1-methy$
21	methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol
22	(3)(4) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-
23	dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-
24	yl)ethyl]amino]methyl]-2-methoxybenzoic acid)(including its
25	optical isomers) and its salts, isomers, and salts of isomers9725
26	(g) Unless specifically excepted or unless listed in another
27	schedule, any material, compound, mixture or preparation containing
28	any of the following narcotic drugs, or their salts calculated as the free
29	anhydrous base or alkaloid, in limited quantities as set forth below:
30	(1) Not more than 1 milligram of difenoxin and not less than 25
31	micrograms of atropine sulfate per dosage unit9167
32	(2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-
33	3-methyl-2-propion-oxybutane)9278
34	(h) Butyl nitrite and its salts, isomers, esters, ethers or their salts.
35	(i) The board may except by rule and regulation any compound
36	mixture or preparation containing any depressant substance listed in
37	subsection (b) from the application of all or any part of this act if the
38	compound, mixture or preparation contains one or more active
39	medicinal ingredients not having a depressant effect on the central
40	nervous system, and if the admixtures are included therein in
41	combinations, quantity, proportion or concentration that vitiate the
42	potential for abuse of the substances-which that have a depressant
43	effect on the central nervous system.}

- Sec. <u>6</u>: {7.} K.S.A. 2016 Supp. 65-4113 is hereby amended to read as follows: 65-4113. (a) The controlled substances or drugs, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section are included in schedule V.
- (b) Any compound, mixture or preparation containing limited quantities of any of the following narcotic drugs which also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
- (1) Not more than 200 milligrams of codeine or any of its salts per 100 milliliters or per 100 grams.
 - (2) Not more than 100 milligrams of dihydrocodeine or any of its salts per 100 milliliters or per 100 grams.
 - (3) Not more than 100 milligrams of ethylmorphine or any of its salts per 100 milliliters or per 100 grams.
 - (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
 - (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
 - (6) Not more than .5 milligram of difenoxin (9168) and not less than 25 micrograms of atropine sulfate per dosage unit.
 - (c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

- (e) Any compound, mixture or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers.
- (f) Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant

H Sub for SB 51—Am. by HCW 30

1	effect on	the central nervous system, including its salts:	
2	(1)	Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]	
3		butanamide) (some trade or other names BRV; UCB-34714;	
4		<i>Briviact</i>)271	0
5	(2)	Ezogabine N-[2-amino-4(4-fluorobenzylamino)-phenyl]-	
6		carbamic acid ethyl ester277	9
7	$\frac{(2)}{(3)}$	Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-	
8		propionamide]274	6
9	(3)(4)	Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid]278	2
10	Sec. <u>-7</u>	E {8.} K.S.A. 2016 Supp. 21-5701, 65-4101, 65-4102, 65-4105	5,
11	65-4107{	, 65-4111 } and 65-4113 are hereby repealed.	
12	Sec. <u>-8</u>	[{9.} This act shall take effect and be in force from and after it	ts
13	publication	on in the Kansas register	